(Q42650874)

English

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 November 2017

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial (English)

1 reference

Europe PubMed Central

4 November 2017

phase I clinical trial

0 references

Parkinson's disease

1 reference

based on heuristic

inferred from title

Charles Warren Olanow

10

object named as

C Warren Olanow

1 reference

Europe PubMed Central

4 November 2017

author name string

William J Marks

1

1 reference

Europe PubMed Central

4 November 2017

Jill L Ostrem

2

1 reference

Europe PubMed Central

4 November 2017

Leonard Verhagen

3

1 reference

Europe PubMed Central

4 November 2017

Philip A Starr

4

1 reference

Europe PubMed Central

4 November 2017

Paul S Larson

5

1 reference

Europe PubMed Central

4 November 2017

Roy Ae Bakay

6

1 reference

Europe PubMed Central

4 November 2017

Robin Taylor

7

1 reference

Europe PubMed Central

4 November 2017

Deborah A Cahn-Weiner

8

1 reference

Europe PubMed Central

4 November 2017

A Jon Stoessl

9

1 reference

Europe PubMed Central

4 November 2017

Raymond T Bartus

11

1 reference

Europe PubMed Central

4 November 2017

publication date

2 April 2008

1 reference

Europe PubMed Central

4 November 2017

Lancet Neurology

1 reference

Europe PubMed Central

4 November 2017

7

1 reference

Europe PubMed Central

4 November 2017

5

1 reference

Europe PubMed Central

4 November 2017

400-408

1 reference

Europe PubMed Central

4 November 2017

Neuropathology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The scientific basis for the current treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Crossroads in GDNF therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Convective delivery of glial cell line-derived neurotrophic factor in the human putamen

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The Purdue pegboard; norms and studies of reliability and validity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of radiotracer imaging in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970065-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(08)70065-6

1 reference

Europe PubMed Central

4 November 2017

1 reference

Europe PubMed Central

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42650874&oldid=1964592286"